Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/46297
Title: European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: a survey of the Association for Acute CardioVascular Care of the ESC and the European branch of the Extracorporeal Life Support Organization
Authors: Van Edom, CJ
Swol, J
Castelein, T
Gramegna, M
Huber, K
Leonardi, S
Mueller, T
Pappalardo, F
Price, S
Schaubroeck, H
Schrage, B
Tavazzi, G
Vercaemst, L
VRANCKX, Pascal 
Vandenbriele, C
Issue Date: 2024
Publisher: OXFORD UNIV PRESS
Source: European Heart Journal. Acute Cardiovascular Care, 13 (6) , p. 458 -469
Abstract: Aims Bleeding and thrombotic complications compromise outcomes in patients undergoing percutaneous mechanical circulatory support (pMCS) with veno-arterial extracorporeal membrane oxygenation (V-A ECMO) and/or microaxial flow pumps like Impella (TM). Antithrombotic practices are an important determinant of the coagulopathic risk, but standardization in the antithrombotic management during pMCS is lacking. This survey outlines European practices in antithrombotic management in adults on pMCS, making an initial effort to standardize practices, inform future trials, and enhance outcomes.Methods and results This online cross-sectional survey was distributed through digital newsletters and social media platforms by the Association of Acute Cardiovascular Care and the European branch of the Extracorporeal Life Support Organization. The survey was available from 17 April 2023 to 23 May 2023. The target population were European clinicians involved in care for adults on pMCS. We included 105 responses from 26 European countries. Notably, 72.4% of the respondents adhered to locally established anticoagulation protocols, with unfractionated heparin (UFH) being the predominant anticoagulant (Impella (TM): 97.0% and V-A ECMO: 96.1%). A minority of the respondents, 10.8 and 14.5%, respectively, utilized the anti-factor-Xa assay in parallel with activated partial thromboplastin time for UFH monitoring during Impella (TM) and V-A ECMO support. Anticoagulant targets varied across institutions. Following acute coronary syndrome without percutaneous coronary intervention (PCI), 54.0 and 42.7% were administered dual antiplatelet therapy during Impella (TM) and V-A ECMO support, increasing to 93.7 and 84.0% after PCI.Conclusion Substantial heterogeneity in antithrombotic practices emerged from participants' responses, potentially contributing to variable device-associated bleeding and thrombotic complications. Graphical Abstract AMICS, acute myocardial infarction-induced cardiogenic shock; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy; DAPT, dual antiplatelet therapy; APTT, activated partial thromboplastin time; ACT, activated clotting time; anti-Xa assay, heparin anti-factor-Xa assay; V-A ECMO, veno-arterial extracorporeal membrane oxygenation.
Keywords: Anticoagulation;Antiplatelets;Mechanical circulatory support;ECMO;Bleeding
Document URI: http://hdl.handle.net/1942/46297
ISSN: 2048-8726
e-ISSN: 2048-8734
DOI: 10.1093/ehjacc/zuae040
ISI #: 001198265800001
Rights: The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.